We are reading a CIGNA plan for pharmaceutical prices and weight loss drugs.

Morning normal. The gray sky is once again rising over the eerie pharmacist campus, but our spirit remains sunny. why? We will show some insights from the morning market. “Every day new days should be wrapped like a valuable gift.” To celebrate the concept, we still brew more stimulating cups and invite us to be with us. There is no need to negotiate a rebate because there is no prescription. And you can use cash. Anyway, today’s choice is strawberry cream. A wonderful choice for those who feel adventure. On the other hand, there are some items here. I hope you have a smashing day. Of course, keep in touch. As always, welcome feedback, criticism and suggestions. …

In order to develop more treatments for rare diseases using scientific progress, the US price of newly launched constraints compared to 2021 is generally high price compared to 2021.A Reuters Found analysis. According to a Reuters survey on 45 pharmaceuticals, the medium annual prices of the new drugs were over $ 370,000 in 2024. According to a study published in JAMA, the average price was $ 180,000 for the 30 drugs sold for the first time by mid -July 2021. According to the IQVIA Institute for Human Data Science, the average launch price in 2023 was $ 300,000 in 2023 and $ 222,000 in 2022, and the proportion of drugs fired for orphans was influenced by less than 200,000 Americans, with 51%in 2019 to 72%in 2024 in 2024 Increased. More than 40% of the orphan launches were for oncology.

Five years after its launch, the unique non -profit drug company has released data that consumers and health plans have saved significant money in general cancer medicine thanks to the “transparent” price model. And the result is a verification of the deployment plan and eventually contributed to more copycat medicines for the US market.Stat explains. The company (CivicAScript) was made as a means of fighting the prices of high pharmaceuticals, even after the dominant branded medicines lost patent protection and the general competitors entered the market. Non -profit organizations, mainly supported by 18 Blue Cross Blue Shield Plan, allowed the use of the first drug of Zytiga prostate cancer, a general version of Zytiga prostate cancer treatment in August 2022. The initial wholesale price was $ 160, and the $ 11 distribution fee paid to the pharmacy was slowed down until it was accepted by the pharmacy and other health plans. After all, GAMBIT is as follows: Between September and December 2023, the patient saved 64%and saved 92%by purchasing generic distributed by Civicascript.